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Abstract— Based on camel milk, a new multicomponent, 
specialized fermented dairy bio-product "Inulakt-Fito" 
was developed for the prevention and treatment of type 2 
diabetes mellitus. Its expressed hypoglycemic, antioxidant 
effect was established in experimental alloxan diabetes. 
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I. INTRODUCTION 
Disease of diabetes is one of the most serious in modern 
endocrinology. According to ethnoecological research, 
type 2 diabetes mellitus at the early stages can be cured 
completely with the help of phytotherapeutic drugs 
(Ashcroft F.M. and Rorsman P., 2004, Abdel-Zaher A.O. 
et al., 2005, Andrade-Cetto A. et al., 2005, Eidi A. et al., 
2006). Now several hundred food and medicinal plants 
are known that can reduce blood glucose levels (Esmaeili 
M.A. and Yazdanparast R., 2004, Arambewela L.S. et al., 
2005, El-Demerdash F.M. et al., 2005). However, the 
mechanism of the sugar-reducing effect of medicinal 
plants has not yet been elucidated (Johnson L. et al., 
2006). One of the reasons for the complexity of managing 
patients with diabetes mellitus is the unsatisfactory 
correction of high glucose in the blood with exogenous 
insulin and other antidiabetic drugs, which requires 
finding additional ways to optimize the level of glycemia 
(Knowler W.C. et al., 2002, Ashcroft F.M. and Rorsman 
P., 2004, Wild S. et al., 2006). For this purpose, not only 
medicines are often used, but also various natural 
compounds for which the effect on carbohydrate 
metabolism is shown. The huge variety of plant material, 
the need to take into account its complex effects, the 
individual approach to the state of health of a diabetic 
person, the presence of possible contraindications or 
complications - all this requires careful testing first in 
model experiments. So, it is extremely important to 
search for and preclinical trials of plant material with 
subsequent clinical studies to create valid 
recommendations for the pharmacological industry. 
In sour-milk products, many of the nutrients of milk 
become more accessible: so proteolytic enzymes of milk 
microflora, partially break down proteins, which increases 
the completeness and speed of their assimilation (Mal G. 
et al., 2007, Shabo Y. et al., 2008, Abbas S, et al., 2013 ). 
Whey milk proteins of camel milk are considered 
biologically active substances and some of them possess 
anti-carcinogenic, antioxidant and immunostimulating 
properties (Al Haj O.A.  et al.,2010, Yadav A. K. et al., 
2015). 
The most promising direction for inclusion in the diet of 
sweeteners as a substitute for sugar is the use of the 
products of processing stevia plants (Stevia Rebaudiana 
Bertoni), a natural sweetener of non-carbohydrate nature, 
possessing unique therapeutic and prophylactic and 
improving properties.  
On the basis of the foregoing, to date, relevant are: 
research, development and creation of a new sour-milk 
biopreparation, in combination with medicinal extracts, 
which in the future is a unique therapeutic and 
prophylactic biopreparation that have no analogues in the 
world's dairy and pharmaceutical industries. 
. 
II. MATERIAL AND METHODS 
The experiment was performed on sexually mature rats 
weighing 180-210 g. of both sexes, grown in a vivarium 
with a standard diet at the Scientific Research Institute of 
Fundamental and Applied Medicine named after B. 
Atchabarov of the Kazakh National Medical University 
named after S.D. Asfendiyarov. Control animals were 
grown under the usual diet regime, without the 
administration of alloxan. The maintenance, care of 
animals and deducing of them from experiment were 
carried out according to (Frode T.S. and Medeiros Y.S., 
2008). 
Induction of diabetes in the animals studied was caused 
by intraperitoneal injection of a 5% solution of alloxan 
monohydrate (AL) at a rate of 100 mg / kg of the animal's 
weight in a 0.9% solution of NaCl (Methodical 
recommendations, 1986). All laboratory animals were 
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previously starved for 24 hours, while access to water was 
not restricted. The Inulakt-Fito sour milk product was 
injected intragastrically at the experimental therapeutic 
dose of 1000 mg / kg once a day throughout the 
experiment. The indices of the group of animals receiving 
the Inulakt-Fito bio-product were compared to the group 
of animals treated with metformin at a dose of 500 mg / 
kg. The studies were performed 7, 14 and 28 days after 
the start of alloxan administration. The level of glucose in 
the blood was determined by the Bionime Rightest 
GM300. Also in the blood serum standard biochemical 
methods were used to study lipid and nitrogen 
metabolism using a set of Lahema reagents (Czech 
Republic). Catalase activity was determined according to 
a previously reported method(Abei H., 1974, Qujeq D. 
and Rezvani T., 2007.), the content of malonic dialdehyde 
in blood serum - according to the method (Kuntz E. and 
Kuntz H.D., 2006) 
The statistical processing of the results was carried out 
using the computer program SPSS (Statistical Package for 
the Social Sciences). 
 
III. RESULTS AND DISCUSSION 
It is known that in the pathogenesis of diabetes mellitus 
one of the key links is the activation of processes of free 
radical oxidation: an imbalance occurs between pro-
oxidants and antioxidants, leading to an excess of free 
radicals and the accumulation of products of free radical 
oxidation. The constant background of impaired 
prooxidant-antioxidant balance in the body in diabetes 
mellitus is one of the causes of death of pancreatic ß-cells 
and structural functional units of other organs, which 
causes the development of multiple organ dysfunction 
(Zhao Y.F. et al., 2005, Masiello, P., 2006). The 
mechanism of diabetic action of alloxan is also associated 
with its damaging effect through the formation of free 
radicals. In particular, it was shown that alloxane 
deposited in ß-cells due to its interaction with zinc 
generates the formation of O2-, OH-, H2O2. Formed free 
radicals and peroxide enter into a chain reaction of 
interaction with molecules of fatty acids of cell 
membranes, destroying them (Federiuk, I.F. et al., 2004) . 
The natural consequence of the decrease in the 
physiological action of insulin, due to its deficiency due 
to the destruction of a large number of β-cells of the 
pancreas, is hyperglycemia(Table 1).  
 
 
 
 
 
 
Table.1: Influence of Inulakt-Fito on biochemical blood 
indices in alloxan diabetes in experimental rats 
Indicators Groups of animals (n = 36) 
Intact Control 
  
(Alloxan) 
Experime
ntal 1 
(Alloxan 
+ nulakt-
Fito) 
Experiment
al 2 
(alloxan+ 
metformin) 
7th day 
Glucose, 
mM / l 
6,01 ± 
0,33 
9,63 ± 
0,10 
6,81 ± 
0,58* 
7,52 ± 
0,09* 
ALT, mE/ L 131,3
±42,5 
191,1±79
,2 
162,4±12
,6 * 
170,0±30,2
* 
АСТ, мЕ/л 618,5
±179,
0 
1076,6±4
46,5 
915,1±10
2,3* 
936,6±93,2
* 
Cholesterol, 
mM / l 
0,63±
0,03 
2,73±0,1
4 
1,43±0,1
6* 
1,45±0,06* 
Urea, mM/ l 4,43±
0,07 
12,63±1,
09 
7,91±0,6
5* 
6,92±0,68* 
Creatinine, 
mmol / l 
73,15
± 1,22 
173,27±9
,50 
129,02±5
,20* 
113,17±7,4
5* 
14th day  
Glucose, 
mM / l 
6,01 ± 
0,33 
12,40 ± 
0,14 
8,06 ± 
0,08* 
9,92 ± 
0,09* 
ALT, mE/ L 131,3
±42,5 
175,2±69
,6 
142,9±11
,2* 
154,7±29,3
* 
АСТ, мЕ/л 618,5
±179,
0 
966,0±44
4,6 
814,4±98
,6* 
852,3±86,1
* 
Cholesterol, 
mM / l 
0,63±
0,03 
2,36±,25 1,38±0,1
1* 
1,30±0,2* 
Urea, mM/ l 4,43±
0,07 
10,65±1,
7 
5,42±0,7
* 
4,53±0,36* 
Creatinine, 
mmol / l 
73,15
± 1,22 
149,35±7
,60 
86,36±4,
83* 
92,6±5,3* 
       28th day  
Glucose, 
mM / l 
6,48±
0,64 
21,9 ± 
0,22 
9,85 ± 
0,10* 
13,9 ± 
0,14* 
ALT, mE/ L  131,3
±42,5 
171,3±10
0,3 
132,8±9,
6* 
143,8±22,9
* 
АСТ, мЕ/л 618,5
±179,
0 
778,6±37
5,9 
757,3±80
,6* 
770,1±92,3
* 
Cholesterol, 
mM / l 
0,63±
0,03 
1,99± 
0,67 
1,13± 
0,08* 
1,15± 0,13* 
Urea, mM/ l 4,43±
0,07 
8,90± 
0,53 
3,18± 
0,18* 
3,56± 0,15* 
Creatinine, 
mmol / l 
73,15
± 1,22 
130,16± 
8,50 
77,60± 
4,12* 
83,80± 
4,50* 
NOTE - * Hereinafter, the difference is significant 
compared to the control group at P≤ 0.05 
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The administration of alloxan to rats is accompanied by a 
significant increase in the level of glucose in the blood, an 
increase in the cholesterol, creatinine and urea in the 
blood serum, which indicates a violation of carbohydrate 
and lipid metabolism, as well as a decrease in the 
functional state of the liver and kidneys.  
Course introduction of rats with alloxan diabetes "Inulakt-
Fito" was accompanied by normalization of carbohydrate 
metabolism. In particular, by the 7th day of observation, 
the blood glucose content under the effect of the tested 
bioproduct decreased by 41%, serum cholesterol 
concentration was reduced by 90%, urea by 59%, 
creatinine by 34%, alanine aminotransferase (ALT) - by 
15%, aspartate aminotransferase (AST) - by 15%. By the 
14th day of observation, the tendency towards 
normalization of biochemical parameters of blood 
persisted. Thus, the glucose level in the blood decreased 
compared to the parameters in the control by 23%. By the 
28th day of observation, the blood glucose content under 
the action of the tested bioproduct was 41% lower than in 
the control group, and normalization of lipid and nitrogen 
metabolism was also observed in experimental diabetes 
mellitus in rats. The drug metformin also had a beneficial 
effect on the course of alloxan diabetes, but in a less 
pronounced degree than Inulakt-Fito. 
Table 2 presents data characterizing the influence of 
Inulakt-Fito on the state of lipid peroxidation (LPO) 
indices and antioxidant protection in conditions of 
damage to the pancreas. As can be seen from Table 2, the 
introduction of this diabetogen has caused the 
development of "oxidative stress", characterized by an 
increase in the intensity of LPO, as evidenced by a 
significant increase in the level of malonic dialdehyde 
(MDA) and a decrease in the activity of antioxidant 
protection - there was a significant inhibition of catalase 
activity. 
Thus, with alloxan diabetes in experimental rats on the 
7th day in serum, the content of malonic dialdehyde is 
significantly increased 2.8 times, in the pancreas 56%. By 
the 14th day after the administration of alloxan, the 
content of lipid peroxidation products in blood of animals 
with alloxan diabetes increased, the content of malonic 
dialdehyde was 3.1 times, in the pancreas - by 78%. By 
28 days with alloxan diabetes, respectively, quadrupled 
by 60% compared with the indices in animals of the intact 
group. Along with the activation of lipid peroxidation 
processes in alloxan diabetes in rats, the antioxidant 
defense of the organism decreases. In particular, reduced 
catalase activity of blood serum in animals of the control 
group by the 7th day of observation is 1.5 times, by the 
14th day - by 1.7 times, by 28 days by 2.2 times. The 
application of Inulakt-Fito resulted in a significant 
improvement in the state of all the studied indicators. In 
particular, the MDA content in the blood serum decreased 
by 1.8 times in 7 days compared to the control. After 14 
days, -58%, 28 days after the start of alloxan 
administration to rats in the blood serum, the MDA 
content was 72% higher than in the animals in the control 
group. The same regularity was noted in the evaluation of 
data on the content of lipid peroxidation products in the 
pancreas.  
 
Table.2: Influence of Inulakt-Fito on LPO processes and 
blood catalase activity in alloxan diabetes in 
experimental rats 
  
  
Indica
tors 
Groups of animals (n = 36) 
In
tact 
Contr
ol 
(Alloxa
n) 
Experim
ental 1 
(Alloxan + 
Inulakt-
Fito) 
Experim
ental 2 
(alloxan + 
metformin) 
        7 th day 
MDA in 
serum, 
μM / ml 
min 
  
2,
35 ± 
0,10 
  
6,72 
± 0,33 
  
4,52 ± 
0,52* 
  
5,72 ± 
0,48* 
MDA in 
the 
pancreas
, nM / g 
  
5,
53 ± 
0,60 
  
8,62 
± 0,80 
  
6,00 ± 
0,60* 
  
7,20 ± 
0,20* 
Catalase
, mcd / l 
2
1,32 
± 
2,01 
14,00 
± 1,32 
18,2 ± 
1,81* 
16,52 ± 
1,63* 
      14 th day 
MDA in 
serum, 
μM / ml 
min 
  
3,
27 ± 
0,15 
  
10,28 
± 0,11 
  
3,95 ± 
0,55* 
  
4,92  ± 
0,65* 
MDA in 
the 
pancreas
, nM / g 
  
5,
53 ± 
0,60 
  
   
9,85 ± 
0,10  
  
       8,00 
± 0,80* 
  
8,85 ± 
0,90* 
Catalase
, mcd / l 
2
1,32 
± 
2,01 
12,01 
± 0,80 
18,62 ± 
1,81* 
15,41 ± 
1,54* 
       28 th day 
MDA in 
serum, 
μM / ml 
min 
  
3,
85 ± 
0,40 
  
15,4 
± 0,16 
  
4,86 ± 
0,50* 
  
7,47 ± 
0,75* 
MDA in 
the 
pancreas
  
5,
55 ± 
  
8,90 
± 0,90 
  
6,02 ± 
0,60* 
  
7,80 ± 
0,80* 
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, nM / g 0,60 
Catalase
, mcd / l 
2
1,35 
± 
2,01 
9,6 ± 
0,85 
17,08 ± 
0,2* 
13,2 ± 
0,13* 
NOTE - * Hereinafter, the difference is significant 
compared to the control group at P≤ 0.05 
 
When the animals were injected with Inulakt-Fito, the 
activity of blood catalase increased according to the 
observation periods by 35, 55 and 78%, as compared to 
the values in the control. The metformin comparison drug 
also inhibited lipid peroxidation processes, but to a lesser 
extent. 
 
IV. CONCLUSION 
As a result of studies on the basis of shubat (camel milk) 
in combination with 5 sugar-reducing medicinal extracts, 
a new multi-component, specialized fermented dairy bio-
product "Inulakt-Fito" (conditional name) was designed 
for the prevention and treatment of type 2 diabetes 
mellitus. The pharmacotherapeutic effect of Inulakt-Fito 
on the parameters characterizing the course of 
experimental diabetes was established. This is due to its 
hypoglycemic and antioxidant properties and depends on 
the complex effects of its biologically active substances. 
The data obtained make it possible to consider the use of 
Inulakt-Fito in the complex treatment of type 2 diabetes. 
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